NeoGenomics completes $310M Clarient acquisition

FORT MYERS — Cancer testing firm NeoGenomics says it has completed its blockbuster deal of Clarient, a unit of GE Healthcare Life Sciences.

Under the terms of the deal, NeoGenomics agreed to pay $80 million in cash, $110 million in preferred stock and 15 million shares of common stock. The $310 million deal makes GE Healthcare a 32% owner of the combined company.

Clarient has operations in Aliso Viejo, Caifl., and Houston and has 415 employees. NeoGenomics' headquarters will remain in Fort Myers and the combination is likely to result in additional employees in Southwest Florida.

“We are very pleased to welcome each of our new employees to the NeoGenomics family, and to begin to add Clarient's outstanding capabilities to our strong service offering,” says Douglas VanOort, the chairman and CEO of NeoGenomics, in a statement.

You can read a recent story in the Business Observer about the impact of the acquisition by clicking here.